[
    {
        "id": "wiki20220301en010_160876",
        "title": "Colorectal cancer",
        "content": "Radiation therapy While a combination of radiation and chemotherapy may be useful for rectal cancer, for some people requiring treatment, chemoradiotherapy can increase acute treatment-related toxicity, and has not been shown to improve survival rates compared to radiotherapy alone, although it is associated with less local recurrence. The use of radiotherapy in colon cancer is not routine due to the sensitivity of the bowels to radiation. As with chemotherapy, radiotherapy can be used as a neoadjuvant for clinical stages T3 and T4 for rectal cancer. This results in downsizing or downstaging of the tumour, preparing it for surgical resection, and also decreases local recurrence rates. For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment. Additionally, when surgery is not possible radiation therapy has been suggested to be an effective treatment against CRC pulmonary metastases, which are developed by 10-15% of people with CRC.",
        "contents": "Colorectal cancer. Radiation therapy While a combination of radiation and chemotherapy may be useful for rectal cancer, for some people requiring treatment, chemoradiotherapy can increase acute treatment-related toxicity, and has not been shown to improve survival rates compared to radiotherapy alone, although it is associated with less local recurrence. The use of radiotherapy in colon cancer is not routine due to the sensitivity of the bowels to radiation. As with chemotherapy, radiotherapy can be used as a neoadjuvant for clinical stages T3 and T4 for rectal cancer. This results in downsizing or downstaging of the tumour, preparing it for surgical resection, and also decreases local recurrence rates. For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment. Additionally, when surgery is not possible radiation therapy has been suggested to be an effective treatment against CRC pulmonary metastases, which are developed by 10-15% of people with CRC.",
        "wiki_id": "206979"
    },
    {
        "id": "wiki20220301en073_34856",
        "title": "Pelvic exenteration",
        "content": "Recovery Pelvic exenteration leaves a person with a permanent colostomy and urinary diversion. A 2015 article reports that pelvic exenteration can provide long-term survival for patients with locally advanced primary rectal carcinoma. The 5-year survival rate of patients undergoing pelvic exenteration following complete resection of disease was 59.3%. Factors shown to influence the survival rate following a pelvic exenteration procedure include age, the presence of metastatic disease, lymph node status, circumferential resection margin, local recurrence of disease, and the need for neoadjuvant therapy. History The procedure was first described by Alexander Brunschwig in 1948. References Surgical oncology Female genital procedures",
        "contents": "Pelvic exenteration. Recovery Pelvic exenteration leaves a person with a permanent colostomy and urinary diversion. A 2015 article reports that pelvic exenteration can provide long-term survival for patients with locally advanced primary rectal carcinoma. The 5-year survival rate of patients undergoing pelvic exenteration following complete resection of disease was 59.3%. Factors shown to influence the survival rate following a pelvic exenteration procedure include age, the presence of metastatic disease, lymph node status, circumferential resection margin, local recurrence of disease, and the need for neoadjuvant therapy. History The procedure was first described by Alexander Brunschwig in 1948. References Surgical oncology Female genital procedures",
        "wiki_id": "3147065"
    },
    {
        "id": "wiki20220301en001_96906",
        "title": "Radiation therapy",
        "content": "Intestinal discomfort The lower bowel may be treated directly with radiation (treatment of rectal or anal cancer) or be exposed by radiation therapy to other pelvic structures (prostate, bladder, female genital tract). Typical symptoms are soreness, diarrhoea, and nausea. Nutritional interventions may be able to help with diarrhoea associated with radiotherapy. Studies in people having pelvic radiotherapy as part of anticancer treatment for a primary pelvic cancer found that changes in dietary fat, fibre and lactose during radiotherapy reduced diarrhoea at the end of treatment. Swelling",
        "contents": "Radiation therapy. Intestinal discomfort The lower bowel may be treated directly with radiation (treatment of rectal or anal cancer) or be exposed by radiation therapy to other pelvic structures (prostate, bladder, female genital tract). Typical symptoms are soreness, diarrhoea, and nausea. Nutritional interventions may be able to help with diarrhoea associated with radiotherapy. Studies in people having pelvic radiotherapy as part of anticancer treatment for a primary pelvic cancer found that changes in dietary fat, fibre and lactose during radiotherapy reduced diarrhoea at the end of treatment. Swelling",
        "wiki_id": "26350"
    },
    {
        "id": "wiki20220301en092_49378",
        "title": "Digestive system surgery",
        "content": "A fellowship (in surgery of the small intestine or of the large bowel, or in pediatric/neonatal lower GI surgery, or in surgery of congenital abnormalities or rare disorders of the lower GI tract, or in emergency/trauma surgery or in cancer surgery of the area), would add on approximately one to three more years. A lower GI surgeon might specialise in the following operations: Colectomy Low (anterior) (LAR) or ultra-low (anterior) resections (ULAR) for rectal cancer, etc. Pelvic exenteration for advanced or recurrent cancer; usually performed in conjunction with other surgeons (e.g., urologists, obstetricians and gynecologists) References General surgery",
        "contents": "Digestive system surgery. A fellowship (in surgery of the small intestine or of the large bowel, or in pediatric/neonatal lower GI surgery, or in surgery of congenital abnormalities or rare disorders of the lower GI tract, or in emergency/trauma surgery or in cancer surgery of the area), would add on approximately one to three more years. A lower GI surgeon might specialise in the following operations: Colectomy Low (anterior) (LAR) or ultra-low (anterior) resections (ULAR) for rectal cancer, etc. Pelvic exenteration for advanced or recurrent cancer; usually performed in conjunction with other surgeons (e.g., urologists, obstetricians and gynecologists) References General surgery",
        "wiki_id": "4510252"
    },
    {
        "id": "wiki20220301en077_63488",
        "title": "Tafazzin",
        "content": "TAFAZZIN has been found to be highly expressed in gastric cancer cells resistant to cisplatin. This resistance was identified to be due to the acquired ability of the cancer cells to undergo epithelial-mesenchymal transition (EMT). The findings that TAFAZZIN is involved in inducing EMT as well as its high levels in these cancer cells may point to its involvement in gastric cancer. TAFAZZIN overexpression has been linked to rectal cancer, prostate cancer, thyroid neoplasm, and cervical cancer. In a study of 140 Swedish rectal cancer patients, TAFAZZIN overexpression was associated with an increase in the expression of oncogenes (FXYD-3 and Livin). It was also found to enhance cell anti-apoptosis response and abnormal cell growth and was even found to be an indicator of rectal cancer's stage, type, and progression. Additionally, the levels of TAFAZZIN were connected to the radiotherapy response of the patients, potentially offering insight into cancer recurrence in patients. A",
        "contents": "Tafazzin. TAFAZZIN has been found to be highly expressed in gastric cancer cells resistant to cisplatin. This resistance was identified to be due to the acquired ability of the cancer cells to undergo epithelial-mesenchymal transition (EMT). The findings that TAFAZZIN is involved in inducing EMT as well as its high levels in these cancer cells may point to its involvement in gastric cancer. TAFAZZIN overexpression has been linked to rectal cancer, prostate cancer, thyroid neoplasm, and cervical cancer. In a study of 140 Swedish rectal cancer patients, TAFAZZIN overexpression was associated with an increase in the expression of oncogenes (FXYD-3 and Livin). It was also found to enhance cell anti-apoptosis response and abnormal cell growth and was even found to be an indicator of rectal cancer's stage, type, and progression. Additionally, the levels of TAFAZZIN were connected to the radiotherapy response of the patients, potentially offering insight into cancer recurrence in patients. A",
        "wiki_id": "3445259"
    },
    {
        "id": "wiki20220301en149_23",
        "title": "Radiation enteropathy",
        "content": "Radiation enteropathy is a syndrome that may develop following abdominal or pelvic radiation therapy for cancer. Many affected people are cancer survivors who had treatment for cervical cancer or prostate cancer; it has also been termed pelvic radiation disease with radiation proctitis being one of the principal features. Signs and symptoms People who have been treated with radiotherapy for pelvic and other abdominal cancers frequently develop gastrointestinal symptoms. These include: rectal bleeding diarrhea and steatorrhea other defecation disorders including fecal urgency and incontinence. nutritional deficiencies and weight loss abdominal pain and bloating nausea, vomiting and fatigue Gastrointestinal symptoms are often found together with those in other systems including genitourinary disorders and sexual dysfunction. The burden of symptoms substantially impairs the patients' quality of life.",
        "contents": "Radiation enteropathy. Radiation enteropathy is a syndrome that may develop following abdominal or pelvic radiation therapy for cancer. Many affected people are cancer survivors who had treatment for cervical cancer or prostate cancer; it has also been termed pelvic radiation disease with radiation proctitis being one of the principal features. Signs and symptoms People who have been treated with radiotherapy for pelvic and other abdominal cancers frequently develop gastrointestinal symptoms. These include: rectal bleeding diarrhea and steatorrhea other defecation disorders including fecal urgency and incontinence. nutritional deficiencies and weight loss abdominal pain and bloating nausea, vomiting and fatigue Gastrointestinal symptoms are often found together with those in other systems including genitourinary disorders and sexual dysfunction. The burden of symptoms substantially impairs the patients' quality of life.",
        "wiki_id": "9905730"
    },
    {
        "id": "wiki20220301en017_58124",
        "title": "Endometrial cancer",
        "content": "The most common site of recurrence is in the vagina; vaginal relapses of endometrial cancer have the best prognosis. If relapse occurs from a cancer that has not been treated with radiation, EBRT is the first-line treatment and is often successful. If a cancer treated with radiation recurs, pelvic exenteration is the only option for curative treatment. Palliative chemotherapy, cytoreductive surgery, and radiation are also performed. Radiation therapy (VBT and EBRT) for a local vaginal recurrence has a 50% five-year survival rate. Pelvic recurrences are treated with surgery and radiation, and abdominal recurrences are treated with radiation and, if possible, chemotherapy. Other common recurrence sites are the pelvic lymph nodes, para-aortic lymph nodes, peritoneum (28% of recurrences), and lungs, though recurrences can also occur in the brain (<1%), liver (7%), adrenal glands (1%), bones (4–7%; typically the axial skeleton), lymph nodes outside the abdomen (0.4–1%), spleen, and",
        "contents": "Endometrial cancer. The most common site of recurrence is in the vagina; vaginal relapses of endometrial cancer have the best prognosis. If relapse occurs from a cancer that has not been treated with radiation, EBRT is the first-line treatment and is often successful. If a cancer treated with radiation recurs, pelvic exenteration is the only option for curative treatment. Palliative chemotherapy, cytoreductive surgery, and radiation are also performed. Radiation therapy (VBT and EBRT) for a local vaginal recurrence has a 50% five-year survival rate. Pelvic recurrences are treated with surgery and radiation, and abdominal recurrences are treated with radiation and, if possible, chemotherapy. Other common recurrence sites are the pelvic lymph nodes, para-aortic lymph nodes, peritoneum (28% of recurrences), and lungs, though recurrences can also occur in the brain (<1%), liver (7%), adrenal glands (1%), bones (4–7%; typically the axial skeleton), lymph nodes outside the abdomen (0.4–1%), spleen, and",
        "wiki_id": "412809"
    },
    {
        "id": "wiki20220301en073_34853",
        "title": "Pelvic exenteration",
        "content": "Uses Pelvic exenteration is an option in cases of very advanced or recurrent cancer, for which less radical surgical options are not technically possible or would not be sufficient to remove all the tumor. This procedure is performed for several types of cancer including genitourinary cancer, and colorectal cancers. It is rarely performed due to common complications. Contraindications Pelvic exenteration may not cure certain cancers. This can happen if there are metastases in the liver, the sidewall of the pelvic cavity, the aortic lymph nodes, or through carcinosis. In these cases, it may not be used. It may also not be used when both ureters are obstructed.",
        "contents": "Pelvic exenteration. Uses Pelvic exenteration is an option in cases of very advanced or recurrent cancer, for which less radical surgical options are not technically possible or would not be sufficient to remove all the tumor. This procedure is performed for several types of cancer including genitourinary cancer, and colorectal cancers. It is rarely performed due to common complications. Contraindications Pelvic exenteration may not cure certain cancers. This can happen if there are metastases in the liver, the sidewall of the pelvic cavity, the aortic lymph nodes, or through carcinosis. In these cases, it may not be used. It may also not be used when both ureters are obstructed.",
        "wiki_id": "3147065"
    },
    {
        "id": "wiki20220301en149_25",
        "title": "Radiation enteropathy",
        "content": "Causes A large number of people receive abdominal and or pelvic radiotherapy as part of their cancer treatment with 60–80% experiencing gastrointestinal symptoms. This is used in standard therapeutic regimens for cervical cancer, prostate cancer, rectal cancer, anal cancer, lymphoma and other abdominal malignancies. Symptoms can be made worse by the effects of surgery, chemotherapy or other drugs given to treat the cancer. Improved methods of radiotherapy have reduced the exposure of non-involved tissues to radiation, concentrating the effects on the cancer. However, as the parts of the intestine such as the ileum and the rectum are immediately adjacent to the cancers, it is impossible to avoid some radiation effects. Previous intestinal surgery, obesity, diabetes, tobacco smoking and vascular disorders increase the chances of developing enteropathy. Pathology Acute intestinal injury",
        "contents": "Radiation enteropathy. Causes A large number of people receive abdominal and or pelvic radiotherapy as part of their cancer treatment with 60–80% experiencing gastrointestinal symptoms. This is used in standard therapeutic regimens for cervical cancer, prostate cancer, rectal cancer, anal cancer, lymphoma and other abdominal malignancies. Symptoms can be made worse by the effects of surgery, chemotherapy or other drugs given to treat the cancer. Improved methods of radiotherapy have reduced the exposure of non-involved tissues to radiation, concentrating the effects on the cancer. However, as the parts of the intestine such as the ileum and the rectum are immediately adjacent to the cancers, it is impossible to avoid some radiation effects. Previous intestinal surgery, obesity, diabetes, tobacco smoking and vascular disorders increase the chances of developing enteropathy. Pathology Acute intestinal injury",
        "wiki_id": "9905730"
    },
    {
        "id": "pubmed23n0081_8506",
        "title": "[Pelvic exenteration in advanced and or recurrent rectal cancer].",
        "content": "Operative procedures of pelvic exenteration which were performed on a 54 yrs male patient with irradiated rectal cancer involving the prostatic gland, perineal skin and gluteal muscles were demonstrated by cinema. Perianal fistula formation and hard fibrotic adhesion between the distal rectum and the sacrum were also seen. As a result, combined resection of the perianal skin, gluteal muscles and distal sacral bone (fourth and fifth sacral and coccygeal vertebrae) was carried out. Fifty four total pelvic exenteration were performed at National Cancer Center Hospital from 1962 to 1985. The procedures were performed as a definitive treatment for the primary tumors in 35 cases (31 males and 4 females) which corresponds to 2.7% of operated primary rectal cancer at the same period and for the locally recurrent cancer in 19 cases (13 males and 6 females). By post operative histopathological examination 35 operations, 28 of 35 primary and 7 of 19 recurrent cases, were assessed as potentially curative. Hospital death rate was 13%; i.e. 7 cases (1 of 35 primary and 6 of 19 recurrent cases). Postoperative survival rates of the 54 patients were calculated by Kaplan-Meier's method. There were 17 survivors among 35 curatively operated patients and 5 yr survival rate was 34%. On the other hand, though 6 patients are surviving, there is no long term survivor (more than 35 months) among 21 patients who were treated by palliative resection.",
        "contents": "[Pelvic exenteration in advanced and or recurrent rectal cancer]. Operative procedures of pelvic exenteration which were performed on a 54 yrs male patient with irradiated rectal cancer involving the prostatic gland, perineal skin and gluteal muscles were demonstrated by cinema. Perianal fistula formation and hard fibrotic adhesion between the distal rectum and the sacrum were also seen. As a result, combined resection of the perianal skin, gluteal muscles and distal sacral bone (fourth and fifth sacral and coccygeal vertebrae) was carried out. Fifty four total pelvic exenteration were performed at National Cancer Center Hospital from 1962 to 1985. The procedures were performed as a definitive treatment for the primary tumors in 35 cases (31 males and 4 females) which corresponds to 2.7% of operated primary rectal cancer at the same period and for the locally recurrent cancer in 19 cases (13 males and 6 females). By post operative histopathological examination 35 operations, 28 of 35 primary and 7 of 19 recurrent cases, were assessed as potentially curative. Hospital death rate was 13%; i.e. 7 cases (1 of 35 primary and 6 of 19 recurrent cases). Postoperative survival rates of the 54 patients were calculated by Kaplan-Meier's method. There were 17 survivors among 35 curatively operated patients and 5 yr survival rate was 34%. On the other hand, though 6 patients are surviving, there is no long term survivor (more than 35 months) among 21 patients who were treated by palliative resection.",
        "PMID": 2434830
    },
    {
        "id": "wiki20220301en167_39840",
        "title": "Particle therapy",
        "content": "Carbon ion radiotherapy Carbon ion therapy (CIRT) uses particles more massive than protons or neutrons. Carbon ion radiotherapy has increasingly garnered scientific attention as technological delivery options have improved and clinical studies have demonstrated its treatment advantages for many cancers such as prostate, head and neck, lung, and liver cancers, bone and soft tissue sarcomas, locally recurrent rectal cancer, and pancreatic cancer, including locally advanced disease. It also has clear advantages to treat otherwise intractable hypoxic and radio-resistant cancers while opening the door for substantially hypo-fractionated treatment of normal and radio-sensitive disease.",
        "contents": "Particle therapy. Carbon ion radiotherapy Carbon ion therapy (CIRT) uses particles more massive than protons or neutrons. Carbon ion radiotherapy has increasingly garnered scientific attention as technological delivery options have improved and clinical studies have demonstrated its treatment advantages for many cancers such as prostate, head and neck, lung, and liver cancers, bone and soft tissue sarcomas, locally recurrent rectal cancer, and pancreatic cancer, including locally advanced disease. It also has clear advantages to treat otherwise intractable hypoxic and radio-resistant cancers while opening the door for substantially hypo-fractionated treatment of normal and radio-sensitive disease.",
        "wiki_id": "12141201"
    },
    {
        "id": "pubmed23n0055_19961",
        "title": "[Posterior pelvic exenteration in the treatment of extraperitoneal rectal cancer in females].",
        "content": "Postoperative recurrence is common in the, posterior vaginal wall and intrapelvic genital organs after conventional Mile's operation for extraperitoneal rectal cancer in female patients. We have performed posterior pelvic exenteration (PPE) since 1954 in an attempt to reduce such recurrences. The results of 208 patients treated by PPE were compared with those of 77 patients treated by conventional Mile's operation during 1954-1986. The 5-year survival rate of PPE was 53.15 +/- 1.87% and that of Mile's operation was 51.84 +/- 1.68%; the increase was not significant as more cases of poorer prognosis were selected for PPE. However, the local recurrence rate was lower after PPE than after conventional Mile's operation (4.33%:20.78%), (P less than 0.01). We believe that PPE is indicated in anterior rectal lesions of Dukes A, B or C stage, ulcerative or infiltrative type, or when the recto-uterine pouch is involved. PPE will not increase the operative risk if close attention is paid to hemostasis, facilitated by clamping cutting and suture ligating the lateral vaginal wall in segments.",
        "contents": "[Posterior pelvic exenteration in the treatment of extraperitoneal rectal cancer in females]. Postoperative recurrence is common in the, posterior vaginal wall and intrapelvic genital organs after conventional Mile's operation for extraperitoneal rectal cancer in female patients. We have performed posterior pelvic exenteration (PPE) since 1954 in an attempt to reduce such recurrences. The results of 208 patients treated by PPE were compared with those of 77 patients treated by conventional Mile's operation during 1954-1986. The 5-year survival rate of PPE was 53.15 +/- 1.87% and that of Mile's operation was 51.84 +/- 1.68%; the increase was not significant as more cases of poorer prognosis were selected for PPE. However, the local recurrence rate was lower after PPE than after conventional Mile's operation (4.33%:20.78%), (P less than 0.01). We believe that PPE is indicated in anterior rectal lesions of Dukes A, B or C stage, ulcerative or infiltrative type, or when the recto-uterine pouch is involved. PPE will not increase the operative risk if close attention is paid to hemostasis, facilitated by clamping cutting and suture ligating the lateral vaginal wall in segments.",
        "PMID": 1667517
    },
    {
        "id": "wiki20220301en073_34852",
        "title": "Pelvic exenteration",
        "content": "Pelvic exenteration (or pelvic evisceration) is a radical surgical treatment that removes all organs from a person's pelvic cavity. It is used to treat certain advanced or recurrent cancers. The urinary bladder, urethra, rectum, and anus are removed. In women, the vagina, cervix, uterus, fallopian tubes, ovaries and, in some cases, the vulva are removed. In men, the prostate is removed. The procedure leaves the person with a permanent colostomy and urinary diversion. Pelvic exenteration often leads to complications, such as infection, kidney damage, embolism, perineal hernia, and problems with the stomas created. However, it increases 5-year survival rate from certain cancers. The procedure was first described by Alexander Brunschwig in 1948.",
        "contents": "Pelvic exenteration. Pelvic exenteration (or pelvic evisceration) is a radical surgical treatment that removes all organs from a person's pelvic cavity. It is used to treat certain advanced or recurrent cancers. The urinary bladder, urethra, rectum, and anus are removed. In women, the vagina, cervix, uterus, fallopian tubes, ovaries and, in some cases, the vulva are removed. In men, the prostate is removed. The procedure leaves the person with a permanent colostomy and urinary diversion. Pelvic exenteration often leads to complications, such as infection, kidney damage, embolism, perineal hernia, and problems with the stomas created. However, it increases 5-year survival rate from certain cancers. The procedure was first described by Alexander Brunschwig in 1948.",
        "wiki_id": "3147065"
    },
    {
        "id": "pubmed23n0086_9376",
        "title": "[Extended surgery for advanced colo-rectal carcinoma (stage IV and V)].",
        "content": "Two hundred fifty-five patients with colo-rectal carcinoma underwent operations in our department between January 1980 and December 1988. The five-year survival rate of stage IV patients (30 cases) was 58%, and the three-year survival rate of stage V patients (44 cases) was 8%. The study for the expression of blood group-related cancer-associated antigens (Lea, CA19-9, etc.) in colo-rectal cancers using immunohistological method and a series of mouse monoclonal antibodies revealed that the stromal staining pattern of CA19-9 means high malignancy with poor prognosis. Nineteen patients with locally invading rectal cancer were submitted to total pelvic exenteration with urinary diversion. The operative mortality rate was 5.3%. A determinate 5-year survival rate of 4.5 was achieved. Fourteen patients with local recurrent lesions of rectal cancer following abdominoperineal resection were submitted to pelvic exenteration combined with sacral resection. Two patients are alive disease free for longer than four years at this writing. This operation assures a better quality of life, lessening of symptoms, disease control and, in selected patients, a cure.",
        "contents": "[Extended surgery for advanced colo-rectal carcinoma (stage IV and V)]. Two hundred fifty-five patients with colo-rectal carcinoma underwent operations in our department between January 1980 and December 1988. The five-year survival rate of stage IV patients (30 cases) was 58%, and the three-year survival rate of stage V patients (44 cases) was 8%. The study for the expression of blood group-related cancer-associated antigens (Lea, CA19-9, etc.) in colo-rectal cancers using immunohistological method and a series of mouse monoclonal antibodies revealed that the stromal staining pattern of CA19-9 means high malignancy with poor prognosis. Nineteen patients with locally invading rectal cancer were submitted to total pelvic exenteration with urinary diversion. The operative mortality rate was 5.3%. A determinate 5-year survival rate of 4.5 was achieved. Fourteen patients with local recurrent lesions of rectal cancer following abdominoperineal resection were submitted to pelvic exenteration combined with sacral resection. Two patients are alive disease free for longer than four years at this writing. This operation assures a better quality of life, lessening of symptoms, disease control and, in selected patients, a cure.",
        "PMID": 2586433
    },
    {
        "id": "pubmed23n0081_508",
        "title": "Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-fluorouracil.",
        "content": "Seventy-nine patients with histopathologically verified unresectable or locally recurrent rectal cancer were nonrandomly allocated to radiotherapy or regional intra-arterial infusion of 5-Fluorouracil (5-FU). Fifteen patients with unresectable and 32 with locally recurrent rectal cancer were subjected to radiotherapy. The absorbed dose was 30 Gy in patients with an unresectable tumor and 45 Gy in patients with locally recurrent rectal cancer. Six patients with unresectable and 26 with locally recurrent rectal cancer received bilateral internal iliac artery infusion of 5-FU in a median dose of 7.5 g. There was no difference in survival between the two methods of treatment. Resection of an initially unresectable tumor could be performed in 5 of 21 patients (4 after radiotherapy and 1 after chemotherapy). All except eight patients had pelvic or perineal pain before treatment. Forty of 43 (93%) patients reported pain relief after radiotherapy and 21 of 28 (75%) after infusion therapy. Ten nonresponders were subjected to alternative treatment (three to intra-arterial infusion and seven to radiotherapy). Five of these ten patients reported complete pain relief and five partial pain relief. After radiotherapy, no significant side effects or complications were observed. The infusion chemotherapy was the cause of death in one patient. In summary, similar palliation was achieved with bilateral iliac artery 5-FU-infusion and radiotherapy. Owing to the complications registered with infusion therapy, radiotherapy must be considered the treatment of choice for these patients. Patients who do not respond to radiotherapy or suffer recurrence of pelvic and perineal pain may receive further palliation from intra-arterial infusion.",
        "contents": "Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-fluorouracil. Seventy-nine patients with histopathologically verified unresectable or locally recurrent rectal cancer were nonrandomly allocated to radiotherapy or regional intra-arterial infusion of 5-Fluorouracil (5-FU). Fifteen patients with unresectable and 32 with locally recurrent rectal cancer were subjected to radiotherapy. The absorbed dose was 30 Gy in patients with an unresectable tumor and 45 Gy in patients with locally recurrent rectal cancer. Six patients with unresectable and 26 with locally recurrent rectal cancer received bilateral internal iliac artery infusion of 5-FU in a median dose of 7.5 g. There was no difference in survival between the two methods of treatment. Resection of an initially unresectable tumor could be performed in 5 of 21 patients (4 after radiotherapy and 1 after chemotherapy). All except eight patients had pelvic or perineal pain before treatment. Forty of 43 (93%) patients reported pain relief after radiotherapy and 21 of 28 (75%) after infusion therapy. Ten nonresponders were subjected to alternative treatment (three to intra-arterial infusion and seven to radiotherapy). Five of these ten patients reported complete pain relief and five partial pain relief. After radiotherapy, no significant side effects or complications were observed. The infusion chemotherapy was the cause of death in one patient. In summary, similar palliation was achieved with bilateral iliac artery 5-FU-infusion and radiotherapy. Owing to the complications registered with infusion therapy, radiotherapy must be considered the treatment of choice for these patients. Patients who do not respond to radiotherapy or suffer recurrence of pelvic and perineal pain may receive further palliation from intra-arterial infusion.",
        "PMID": 2424584
    }
]